RxDoctor Payments Data

Douglas Kress, MD

Dermatology · Wexford, PANPI 1396748950

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,595,925 of the $1,951,881 with a category attached, or 81.8%. 37 manufacturers reported payments, led by Sanofi at 33.4% of the total. Among dermatology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,951,881in general payments, 2019–2025

Across 2,172 payments — averaging $898.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$651K
  • Regeneron Healthcare Solutions, Inc.$594K
  • AbbVie$272K
  • Pfizer$95K
  • Incyte Corporation$83K
  • Galderma Laboratories, L.p.$52K
  • plus $205K from 31 others

What the payments were for

  • Consulting fees$132,2077%
  • Speaking & faculty fees$1,595,92582%
  • Travel & lodging$175,3269%
  • Food & beverage$47,7762%
  • Education$5300%
  • Gifts$1170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,951,881 in reported general payments places this provider in the 95th percentile of 626 dermatology providers in Pennsylvania.

See all dermatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,723
Medicare patients
12
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clindamycin Phosphate19$1,236
Ketoconazole29$499

Paid to pharmacies, not to this prescriber.

Other dermatology in Wexford

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →